Choosing Between — Enzalutamide, Abiraterone and Apalutamide

Switching is possible and happens in clinical practice. If fatigue on enzalutamide, a skin rash on apalutamide or fluid retention on abiraterone is significantly affecting your daily life, tell your oncologist clearly — describe how it is actually affecting you, not just that it is happening. Switching carries its own considerations, including whether these drugs share some resistance patterns, but a conversation about it is entirely reasonable. Tolerating something that is affecting your quality of life is not expected or required.

They work through different mechanisms, so a simple stronger-or-weaker comparison is not meaningful. All three are established treatments recommended in overlapping settings by NCCN, ASCO and ESMO, and all have substantial evidence supporting them. The choice is not about one being superior overall — it is about which fits your specific cancer stage, other health conditions and side effect profile. If you are asking because you want reassurance your prescription is appropriate, ask your oncologist directly why they chose this particular drug for you.

For most patients, the prednisone dose used alongside abiraterone is low enough that long-term steroid side effects are limited. It is worth being aware of, not alarmed by. If you have diabetes, even a low steroid dose can raise blood glucose, and you may need closer monitoring. Tell your team too if you have osteoporosis or a history of frequent infections. These are not reasons to avoid abiraterone — they are reasons to monitor more carefully while you are on it.

Standard abiraterone tablets are absorbed very differently depending on whether food is present. A meal can substantially change the amount that enters the bloodstream, which alters both the effect and the side effect profile. The original tablet is taken at least an hour before food or two hours after a meal. Some newer formulations are designed to be taken with a light meal — ask your pharmacist or oncologist which version you have and exactly how to take it. Taking it incorrectly is a common and preventable problem.

Generic abiraterone is widely available in India and is the most affordable of the three drugs by a considerable margin. Generic medicines contain the same active ingredient at the same dose and are required to meet regulatory standards for bioequivalence — they work the same way. For enzalutamide and apalutamide, generics have more limited availability in India currently, though this is changing. If cost is a concern, discuss it with your oncologist. Patient-assistance programmes through manufacturers are sometimes also worth asking about.

When a cancer stops responding to one androgen-receptor inhibitor, there is evidence of partial cross-resistance, meaning switching to another drug in the same class may offer only a limited response. Your oncologist will usually discuss other options at that point — which may include chemotherapy, radionuclide therapy if applicable, or a clinical trial. It does not mean treatment is over; it means the plan needs reassessing. This is a conversation worth having with your oncologist before you need it, so you go into it informed rather than in crisis.